Page 151 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY
P. 151
PREDICTORS OF FREQUENT EXACERBATIONS IN (EX)SMOKING AND NEVER SMOKING ADULTS WITH SEVERE ASTHMA
Table 3. Comparison of never smokers with and without frequent exacerbations. Non-exacerbator (n=42) Exacerbator (n=28)
Age, years
Sex, % female
Age of asthma onset
Asthma duration, years
BMI, kg/m2
Positive family history of asthma, %
Pack years
ICS dose *
Chronic OCS use, %
Atopy, %
Chronic rhinosinusitis, %
GERD, %
ACQ-6 score
AQLQ 5.0
(13)
(11) (2-15) (4.2)
(500-1250)
(1.0) (1.0)
(21) (14) (21) (14) (1.8)
Pb FEV1, % predicted
Pb FEV1/FVC, % predicted RV/TLC ratio, % predicted TLCOc/VA, % predicted PC20 (methacholine), mg/ml
FeNO, ppb
Blood neutrophils, 109 cells/L
Blood eosinophils, 109 cells/L
Total IgE, kU/L
Sputum neutrophil %
Sputum eosinophil %
92 (18) 84 92 (15) 89 94 (19) 98 98 (17) 103 5.5 (6.1) 2.0
23 (13-45) 30 4.1 (3.1-5.5) 4.5 0.17 (0.10-0.30) 0.28 54 (27-229) 100 64.1 (3 7.6-86.1) 72.4 1.9 (0.2-13.7) 6.7
0.473 0.237 0.051 0.195 0.872 0.589
50 (14) 51 83 68 41 (14) 39 5.0 (1-16) 8.5
28.7 (6.1) 28.9 40 21 NA NA 625 (500-1000) 1000 21 39 38 54 30 33 46 27 1.8 (0.8) 2.2 (1.2) 4.5
p-value 0.852 0.131 0.537 0.269 0.853 0.132 NA 0.080 0.105 0.202 0.776 0.134 0.087 0.154
0.092 0.481 0.414 0.245 0.012
(15-61)
(3.6-6.3)
(0.12-0.65)
(48-271)
(36.8-83.6)
(0.2-33.8)
fluticasone equivalent. Pb:
Data presented as percentage, mean (SD) or median
postbronchodilator. Ppb: parts per billion.
(interquartile range). * ICS dose in
3
149
